DEVELOPING TOMORROW’S CANCER THERAPIES. TODAY.
- Private – spin-out from APEIRON Biologics AG
- Launched in January 2022
- Based in Vienna, Austria
- Highly experienced management team with strong scientific and capital markets expertise
- In-house acumen in discovery, development, clinical, CMC and financial operations
- Targeting funding round in H2 2022
Investment case: Excellent basis for future value growth
- Innovative IO-focused operations
- Unencumbered IO projects
- Proprietary EPiC cell-therapy platform
- Short treatment times in out-patient setting
- Uses the patient’s fresh immune cells
- Validated, safe, optimized process
- Clinical stage lead candidate APN401
- Immune-reactive small molecule project for oral application
- In-house Innovation Hub driving long-term pipeline growth
Innovative immuno-oncology pipeline
Why are we targeting Cbl-b?
-
Modulating Cbl-b is central to fighting tumor cells in a broad range of tumor indications
-
Cbl-b is involved in several negative regulatory pathways
-
Cbl-b deficiency activates a variety of immune cells for tumor destruction
Lead clinical program APN401: first-in-class Cbl-b silencing
- Robust pre-clinical data
- First-in-human trial (single & multiple dose)
- APN401 was safe and well tolerated; first signs of clinical efficacy
- Ongoing Phase 1b multi-center study in solid tumors:
- Dose level 1 and 2 completed (safe and well tolerated)
- Dose level 3 ongoing
- First confirmation of enhanced anti-tumor immunity (DL 1)
EPiC – our GMP-certified cell-therapy platform
-
Patient-centric – short treatment times (<24 hours) in out-patient setting
-
Uses patient’s own fresh immune cells
-
Multiple targets (e.g., siRNA, mRNA)
-
Multiple treatment options (no freezing necessary)
Key differentiators vs conventional cell therapies
For further information, please visit our main website:
Innovative immuno-oncology pipeline
| Targets | Projects | EARLY STAGE | CLINICAL | |||
| DISCOVERY | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 | ||
| Cbl-b via EPiC | APN401 autologous cell therapy targeting Cbl-b first-in-human trial completed | |||||
| INV441 adoptive cell therapy – TIL activation in solid tumors | ||||||
| Novel IO targets | INV501 oral application for tumor-specific immune activation | |||||
Why are we targeting Cbl-b?
-
Modulating Cbl-b is central to fighting tumor cells in a broad range of tumor indications
-
Cbl-b is involved in several negative regulatory pathways
-
Cbl-b deficiency activates a variety of immune cells for tumor destruction
Lead clinical program APN401: first-in-class Cbl-b silencing
- Robust pre-clinical data
- First-in-human trial (single & multiple dose)
- APN401 was safe and well tolerated; first signs of clinical efficacy
- Ongoing Phase 1b multi-center study in solid tumors:
- Dose level 1 and 2 completed (safe and well tolerated)
- Dose level 3 ongoing
- First confirmation of enhanced anti-tumor immunity (DL 1)
EPiC – our GMP-certified cell-therapy platform
-
Patient-centric – short treatment times (<24 hours) in out-patient setting
-
Uses patient’s own fresh immune cells
-
Multiple targets (e.g., siRNA, mRNA)
-
Multiple treatment options (no freezing necessary)
Key differentiators vs conventional cell therapies
For further information, please visit our main website:
